NEW YORK, NY / ACCESSWIRE / October 21, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Portland General Electric Company (NYSE:POR)
Class Period: February 13, 2020 - August 24, 2020
Lead Plaintiff Deadline: November 2, 2020
The POR lawsuit alleges Portland General Electric Company made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) PGE lacked effective internal controls over its energy trading practices; (2) PGE personnel had entered energy trades during 2020, with increasing volume accumulating late in the second quarter and into the third quarter, that created significant negative financial exposure for PGE; (3)as a result, the Company was reasonably likely to incur significant losses; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in POR: http://www.kleinstocklaw.com/pslra-1/portland-general-electric-company-loss-submission-form?id=10348&from=1
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Class Period: February 11, 2020 - August 10, 2020
Lead Plaintiff Deadline: November 2, 2020
The complaint alleges that during the class period Fennec Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the manufacturing facilities for PEDMARK, the Company's sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in FENC: http://www.kleinstocklaw.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?id=10348&from=1
Mesoblast Limited (NASDAQ:MESO)
Class Period: April 16, 2019 - October 1, 2020
Lead Plaintiff Deadline: December 7, 2020
According to the complaint, Mesoblast Limited allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in MESO: http://www.kleinstocklaw.com/pslra-1/mesoblast-limited-loss-submission-form?id=10348&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899, or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm